Dabigatran-related leukocytoclastic vasculitis. BMJ Case Rep 2017 Jan 04;2017
Date
01/06/2017Pubmed ID
28052946Pubmed Central ID
PMC5256400DOI
10.1136/bcr-2016-217423Scopus ID
2-s2.0-85009070233 (requires institutional sign-in at Scopus site) 16 CitationsAbstract
Dabigatran is a non-vitamin K antagonist oral anticoagulant that has been approved for atrial fibrillation and prevention of venous thromboembolism. Its use has been increasing in the USA since serum drug levels do not need monitoring. To date, no significant skin side effects have been reported other than 4 cases of non-specific skin lesion and 2 cases of leukocytoclastic vasculitis (LCV), which is a small vessel inflammatory disease that presents as palpable purpura in lower extremities. We present a man aged 57 years with chronic deep vein thrombosis who developed palpable purpura, petechiae, swelling in lower extremities, torso and distal upper extremities on the third day after dabigatran initiation. The present case highlights the potential risk for LCV with dabigatran use and provides insight into its management.
Author List
An J, Garje R, Wanat KA, Leone JPAuthor
Karolyn A. Wanat MD Chair, Professor in the Dermatology department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AntithrombinsDabigatran
Diagnosis, Differential
Humans
Male
Middle Aged
Vasculitis, Leukocytoclastic, Cutaneous
Venous Thrombosis
